News | May 27, 2021
Strides Pharma Science posts consolidated PAT of Rs. 46.08 Cr in Q4FY21
Strides Pharma Science reported total income of Rs.3367.29 crores during FY 2020-21
Strides Pharma Science reported total income of Rs.3367.29 crores during FY 2020-21
The company reported net profit for FY21 at Rs. 2,903.8 crore, lower by 23% over last year
With the surge of infections in India in the recent days AmphoTLC will address the country's acute liposomal amphotericin B shortage
Revenue from operations for the year ended March 31, 2021 is ?2,239 crore
BALflu is approved by DCGI for emergency use for the treatment of COVID-19
Posaconazole is a triazole antifungal agent indicated for treating mucormycosis patients
The turnover of its NPNC Formulations Division (IKKT Undertaking) for FY 2020-2021 is Rs.21.33 Cr
The antibody cocktail is to be administered for the treatment of mild to moderate COVID-19
This marks Glenmark's first synthetic decapeptide injectable approval
The company plans to enter the EU markets in FY22
Subscribe To Our Newsletter & Stay Updated
